Investor Update
Basel, 25 May 2009
Roche Investor Events: ASCO 2009
Analyst briefings on data presented at ASCO: Sunday, May 31 and Monday, June 1
We are pleased to invite you to two analyst briefings to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology meeting (ASCO) in Orlando (May 29 – June 2, 2009).
Roche and Genentech are offering two joint analyst briefings, one on Sunday May 31 and one on Monday June 1, to cover ASCO newsflow in a timely manner. Several presentations will be given by leading investigators/key opinion leaders as well as Roche and Genentech management.
Venue: Hotel Rosen Shingle Creek (for both events)
Meeting room: “Panzacola H1” on the first floor of the hotel convention center
9939 Universal Boulevard
Orlando, FL 32819
http://www.rosenshinglecreek.com
We are also pleased to invite you to a buffet reception on June 1 following to the second analyst briefing.
In order to assist you, we have prepared an ASCO planner providing an overview of oral and poster abstracts relevant to us, including indication of time and venue of the presentation. This planner can be downloaded from our website via http://www.roche.com/asco-planner-2009.pdf.
Please see below for details on each of our ASCO Analyst Briefings.
Roche ASCO Analyst Briefing (part 1)
Date/Time:Sunday, 31 May, 2009
6.30 pm to 8.00 pm Eastern daylight time EDT (Orlando)
0.30 am to 2.00 am Central European Summer time CEST (Zurich) on June 1st
11.30 pm to 01.00 am British Summer time BST (London)
Highlights:
Avastin: NSABP C-08 data overview followed by Q&A
Carmen J. Allegra, M.D., University of Florida, Shands Cancer Center,
Professor and Chief, Division of Hematology/Oncology, Department of Medicine
Philippe Bishop, M.D. , Vice President, Clinical Development, Avastin, Genentech
Tarceva: SATURN and ATLAS data overview
Ivan Melezinek, M.D., Ph.D., (SATURN), Clinical Science Leader, Tarceva, Roche
Mark “Kip” Benyunes, M.D., (ATLAS, summary), Senior Group Director,
Clinical Hematology/Oncology, Genentech
Milestones/closing remarks
Hal Barron, M.D., Executive Vice President, Global Development, and Chief
Medical Officer, Genentech
Other key members of Roche and Genentech product teams will also be available for Q&A
Dial in to the conference 10-15 min prior to the scheduled start using the following numbers:
+41 (0) 91 610 56 00 (EU and RoW)
+44 (0) 207 107 06 11 (UK)
+1 (1) 866 291 4166 (USA – toll free)
Alternatively a live audio webcast can be accessed via http://ir.roche.com. The presentation slides will be available from the IR website at http://ir.roche.com following to the closure of the ASCO meeting. A replay of the conference call will be available one hour after the conference call, for 48 hours. Access is by dialing:
+41 91 612 43 30 (EU and RoW)
+44 207 108 62 33 (UK)
+1 (1) 866 416 25 58 (USA)
and will be asked to enter the ID 16543 followed by the # sign.
A replay of the webcast will be available on demand at http://ir.roche.com.
Roche ASCO Analyst Briefing (part 2)
Date/Time:Monday, 1 June, 2009
6.30 pm to 8.00 pm Eastern daylight time EDT (Orlando)
0.30 am to 2.00 am Central European Summer time CEST (Zurich) on June 2nd
11.30 pm to 01.00 am British Summer time BST (London)
followed by a buffet reception next door to the meeting room
Highlights:
Herceptin: ToGA followed by Q&A
Eric Van Cutsem, M.D., Ph.D., Department of Radiotherapy, University Hospitals Leuven, Belgium
Avastin Breast Cancer: RIBBON-1 and AVADO clinical data overview
Stefan Frings, M.D., Ph.D., Lifecycle Leader, Avastin BC/Gyn, Roche
Roche Group Early-stage Oncology pipeline
Catherine Wheeler, M.D., Executive Director, Pharma Development Clinical Oncology, Roche
Sean Bohen, M.D., Ph.D., Vice President, Early Development, Genentech
Other key members of Roche and Genentech product teams will also be available for Q&A
Dial in to the conference 10-15 min prior to the scheduled start using the following numbers:
+41 (0) 91 610 56 00 (EU and RoW)
+44 (0) 207 107 06 11 (UK)
+1 (1) 866 291 4166 (USA – toll free)
Alternatively a live audio webcast can be accessed via http://ir.roche.com. The presentation slides will be available from the IR website at http://ir.roche.com following to the closure of the ASCO meeting. A replay of the conference call will be available one hour after the conference call, for 48 hours. Access is by dialing:
+41 91 612 43 30 (EU and RoW)
+44 207 108 62 33 (UK)
+1 (1) 866 416 25 58 (USA)
and will be asked to enter the ID 15578 followed by the # sign.
A replay of the webcast will be available on demand at http://ir.roche.com.